CUTISS receives new patent in the USA

(CONNECT) CUTISS has a new patent in its hands: The spin-off from the University of Zurich, which is based in the Bio-Technopark Schlieren-Zurich and was founded in 2017, has been granted protection from the US Patent Office for its disposable system and process for producing a compressed hydrogel.

According to a statement from the biotech company, the patented invention relates to a core area of the tissue engineering process by enabling the production of compressed hydrogels in a completely disposable format. According to the patent, this approach is designed to reduce the risk of contamination, simplify the workflow, reduce production complexity and enable improved quality and scalability in the production of transplants.

According to the information provided, the new patent from the USA strengthens the intellectual property portfolio of the company led by CEO and co-founder Dr. Daniela Marino, COO Kathi Mujynya Ludunge and CIO Dr. Vincent Ronfard. Above all, it supports its overarching strategy to industrialize personalized skin tissue therapies through robust, standardized and scalable manufacturing approaches for its lead product denovoSkin.

Under this name, CUTISS has developed a process for the production of human living skin for personalized application. CUTISS' lead product is currently in a phase 3 clinical trial in Switzerland and the European Union and has orphan drug designation for the treatment of burns, granted by Swissmedic, the European Medicines Agency and the US Foodand Drug Association. ce/mm